Uncategorized
Phase 3 studies of lampalizumab for geographic atrophy enrolling
MIAMI — Phase 3 studies of lampalizumab are underway based on results of the phase 2 MAHALO study, which showed evidence that treatment slows the rate of geographic atrophy progression in patients with age-related macular degeneration, a speaker told colleagues.“Certainly there is a significant unmet medical need with regard to geographic atrophy,” Carl D. Regillo, MD, said at Angiogenesis, Exudation, and Degeneration 2015. “There’s more than 5 million people worldwide affected by GA, and there’s no effective treatment.”